Australia markets closed

Argenica Therapeutics Limited (AGN.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.8400-0.0050 (-0.59%)
At close: 04:10PM AEST

Argenica Therapeutics Limited

117 Broadway
Unit 4
Nedlands, WA 6009
61 8 9329 3396

Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Liz Dallimore B.Sc., M.B.A., Ph.D.CEO, MD & Director276.25kN/AN/A
Ms. Emma WaldonCFO & Company SecretaryN/AN/A1976
Prof. Bruno Philip MeloniChief Scientific OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.

Corporate governance

Argenica Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.